| Kelly B Stuart, MD | |
|
Pmg Cedar Obgyn, 201 Cedar Se, Albuquerque, NM 87106 | |
| (505) 563-6000 | |
| (505) 563-6060 |
| Full Name | Kelly B Stuart |
|---|---|
| Gender | Female |
| Speciality | Obstetrics/gynecology |
| Experience | 22 Years |
| Location | Pmg Cedar Obgyn, Albuquerque, New Mexico |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1548312929 | NPI | - | NPPES |
| 19670087 | Medicaid | NM |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207VX0000X | Obstetrics & Gynecology - Obstetrics | MD2007-0260 (New Mexico) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Presbyterian Hospital | Albuquerque, NM | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Presbyterian Healthcare Services | 9234041708 | 1099 |
News Archive
Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, announced today the establishment of a new High-level global Commission on Noncommunicable Diseases (NCDs).
In a new report released today, John Doyle, Vice President and Practice Leader for Quintiles Consulting, and an expert on pharmaceutical market access, explores the complex issue of comparative effectiveness research (CER) and its strategic importance in successful and efficient biopharmaceutical development.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish nine new Research Units. This decision was taken by the DFG's Senate at its February session in Bonn. The new groups are intended to provide researchers with the opportunity to address current and urgent issues in their fields and to develop new research strategies.
A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by the National Institutes of Health.
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
› Verified 7 days ago
| Entity Name | Presbyterian Healthcare Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1104802354 PECOS PAC ID: 9234041708 Enrollment ID: O20031103000603 |
News Archive
Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, announced today the establishment of a new High-level global Commission on Noncommunicable Diseases (NCDs).
In a new report released today, John Doyle, Vice President and Practice Leader for Quintiles Consulting, and an expert on pharmaceutical market access, explores the complex issue of comparative effectiveness research (CER) and its strategic importance in successful and efficient biopharmaceutical development.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish nine new Research Units. This decision was taken by the DFG's Senate at its February session in Bonn. The new groups are intended to provide researchers with the opportunity to address current and urgent issues in their fields and to develop new research strategies.
A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by the National Institutes of Health.
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kelly B Stuart, MD Po Box 26666, Phs Provider Enrollment, Albuquerque, NM 87125-6666 Ph: (505) 923-5356 | Kelly B Stuart, MD Pmg Cedar Obgyn, 201 Cedar Se, Albuquerque, NM 87106 Ph: (505) 563-6000 |
News Archive
Dr Tedros Adhanom Ghebreyesus, Director-General of the World Health Organization, announced today the establishment of a new High-level global Commission on Noncommunicable Diseases (NCDs).
In a new report released today, John Doyle, Vice President and Practice Leader for Quintiles Consulting, and an expert on pharmaceutical market access, explores the complex issue of comparative effectiveness research (CER) and its strategic importance in successful and efficient biopharmaceutical development.
The Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is to establish nine new Research Units. This decision was taken by the DFG's Senate at its February session in Bonn. The new groups are intended to provide researchers with the opportunity to address current and urgent issues in their fields and to develop new research strategies.
A pre-exposure prophylaxis (PrEP) regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by the National Institutes of Health.
Neuralstem, Inc. (NYSE Amex: CUR) today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to commence a Phase I trial to treat Amyotrophic Lateral Sclerosis (ALS or Lou Gehrig's disease) with its spinal cord stem cells.
› Verified 7 days ago
Patrick R Mcginnis, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 5150 Journal Center Blvd Ne, Albuquerque, NM 87109 Phone: 505-727-7600 Fax: 505-727-7640 | |
Kelly Drescher, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 201 Cedar St Se Ste 5600, Albuquerque, NM 87106 Phone: 505-563-6000 Fax: 505-563-6060 | |
Dr. Jennifer Coffey Gill, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Presbyterian Healthcare Services, 6100 Pan American Freeway Ste 450, Albuquerque, NM 87109 Phone: 505-823-8787 Fax: 505-792-1978 | |
Shannon Carr, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2211 Lomas Blvd Ne, 4th Floor Ambulatory Care Ctr, Albuquerque, NM 87106 Phone: 505-272-2245 Fax: 505-272-1109 | |
Jacquelyn A Blackstone, DO Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 2211 Lomas Blvd Ne, Albuquerque, NM 87106 Phone: 505-272-3120 Fax: 505-272-8060 | |
Sophie Peterson, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 6100 Pan American Freeway, Ste 450, Albuquerque, NM 87109 Phone: 505-823-8787 Fax: 505-823-8788 | |
Douglas J Krell, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 4705 Montgomery Ne, Suite 301-302, Albuquerque, NM 87109 Phone: 505-254-6500 Fax: 505-254-6532 |